Navigation Links
Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
Date:9/7/2007

5-FU, a cytotoxic (cell-killing) drug. Because many cancers have higher levels of TP than does normal tissue, more 5-FU is delivered to the tumor than to other tissue.

Conventional, approved Xeloda dosing on a 14-on/7-off schedule is 1250 mg/m(2) twice daily (total of 2500 mg/m(2)/day).

A clinically important drug interaction between Xeloda and warfarin has been demonstrated; altered coagulation parameters and/or bleeding and death have been reported. Clinically significant increases in prothrombin time (PT) and INR have been observed within days to months after starting Xeloda, and infrequently within one month of stopping Xeloda. For patients receiving both drugs concomitantly, frequent monitoring of INR or PT is recommended. Age greater than 60 and a diagnosis of cancer independently predispose patients to an increased risk of coagulopathy.

Xeloda is contraindicated in patients who have a known hypersensitivity to 5-fluorouracil, and in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. Xeloda is contraindicated in patients with severe renal impairment. For patients with moderate renal impairment, dose reduction is required.

The most common adverse events (greater than or equal to 20%) of Xeloda monotherapy were diarrhea, nausea, stomatitis and hand-foot syndrome. As with any cancer therapy, there is a risk of side effects, and these are usually manageable and reversible with dose modification or interruption.

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative products and services that address prevention, diagnosis and treatment of diseases, thus enhancing people's health and quality of life. An employer of choice, in 2006, Roche
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 /PRNewswire-iReach/ -- ChemImage will present a workshop ... New Zealand Forensic Science Society,s 22 nd ... Adelaide, Australia .  Forensic Scientists will ... that hyperspectral imaging can bring to examination procedures. ... Director of Product Development at ChemImage, will host ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, ... (OTCQB: DMPI) ("DelMar" "the Company") today announced the filing ... Company recently changed its fiscal year end to June ... its common stock on a national securities exchange in ... as filed with the United States Securities Exchange Commission ...
(Date:8/28/2014)... 2014 Reportlinker.com announces that a new ... North America Aesthetic Lasers and Energy ... http://www.reportlinker.com/p02343466/North-America-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html North America Aesthetic ... Summary GlobalData,s new report, "North America ... 2020", provides key market data on the North ...
Breaking Medicine Technology:ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 4North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 6North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 7North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 8North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 9North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 10North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 11North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 12North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 13North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 14North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 15North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 16
... The Blumenthal,Cancer Center at Carolinas Medical Center (CMC) ... in a study that could lead to individualized,treatments ... first hospital system,outside Moffitt,s home state of Florida ... CMC will enroll more than 2,300 patients in,the ...
... PCOP ), an innovator in the discovery and ... completion of recruitment,in the company,s multi-center Phase 2a ... product candidate. The objective of the Phase,2a randomized, ... and safety of 200 and 500 mg of ...
Cached Medicine Technology:CMC, Moffitt Partner to Study Cancer 2Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA) 2Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA) 3Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA) 4
(Date:8/30/2014)... After offering hyperbaric oxygen therapy ... past several years, Dr. Roy Schmidt and the ... a scholarship program for veterans who have been ... held this summer to discuss veterans’ needs ( ... shed light on the large number of veterans ...
(Date:8/30/2014)... August 30, 2014 Market Research ... 2009-2019 is a professional and in-depth market survey ... report firstly reviews the basic information of Cell ... The report then explores global and China’s top ... capacity, Production value, and market share etc. The ...
(Date:8/30/2014)... Hundreds of Byetta lawsuits ( http://www.byettalawsuit.com ... forward in U.S. courts, Bernstein Liebhard LLP reports. According ... 31, 2014, Byetta and Bydureon (an extended-release version of ... that allege the drugs caused pancreatitis, pancreatic cancer and ... claims are pending in a multidistrict litigation underway in ...
(Date:8/30/2014)... August 30, 2014 Continuing to meet ... is expanding with the addition of a new doctor ... who has provided leading-edge skin care in Grand Rapids ... , “As a doctor, my passion is making ... partnering with Forefront Dermatology, I’m better able to focus ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 In today’s world, ... difficult to get. Snoring and sleep apnea (a medical problem ... people and their bed partners of the rest they need ... of the population snores and 20 million people in the ... have been diagnosed and treated; and of those treated, many ...
Breaking Medicine News(10 mins):Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 3Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 4Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Expanding Care at the Forefront of Dermatology 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... The diagnosis of multiple sclerosis using the magnetic resonance ... the new findings// published by the BMJ. ... the National Institute for Health and Clinical Excellence (NICE) ... sclerosis. Although its accuracy has been assessed, the evidence ...
... ministry have denied the presence of any bird flu infection ... flu,' said Jose Angel del Valle, the ministry's animal health ... in the U.S. commodities markets, leading to a reduction in ... the death of a duck, in the town of Nogales, ...
... government will donate $35,700 to a clinic here ... ,The donation, in Australian dollars, was announced ... ,"The donation again demonstrates the Australian ... she said. ,"By funding this clinic, ...
... of Health in China has revealed that just over 67 ... HIV/AIDS//. ,This survey was conducted recently by a research ... from 1,919 respondents in 24 colleges of 19 cities.,The results ... aware of how HIV/AIDS is transmitted and 75.6 per cent ...
... non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) or COX-2-selective NSAIDs, ... NEXIUM? (esomeprazole magnesium). // These results were from ... the April 2006 edition of the American Journal ... such as ibuprofen, naproxen and aspirin, and newer ...
... Nitish Kumar is all for a giving a boost to ... tomato and green vegetables// at their official residence, he wants ... farming. ,Nitish Kumar comes from a family with ... practitioner in his home district of Nalanda. Even today Nitish's ...
Cached Medicine News:Health News:MRI Scan Insufficient For Diagnosing Multiple Sclerosis 2Health News:Patients on NSAIDS have reduced gastric ulcers risk by Nexium? 2
... TheraSeed® Pd-103 implant is a combination of ... visibility that makes TheraSeed® treatment an ideal ... be confident that every TheraSeed® implant order ... which is required by clinicians who must ...
... designed to help you achieve one important ... procedure. All needles are engineered for exceptional ... for smooth entry and exit. A broad ... an ideal match with procedural needs and ...
... a combination of innovative design, consistently reliable ... I-125 implant an ideal choice for your ... every BrachySource I-125 implant order is backed ... required by clinicians who must meet the ...
... drainage from the ureteropelvic junction to the ... segment with no sideports prevents postoperative narrowing ... of the ureteral wall to the stent. ... one-time use. CAUTION: Periodic evaluation is advised; ...
Medicine Products: